Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand

Show simple item record Radke, S en Petousis-Harris, Helen en Watson, D en Gentles, Dudley en Turner, Nicola en 2017-03-15T01:20:34Z en 2016-11-01 en 2017-01-03 en
dc.identifier.citation Vaccine, 03 January 2017, 35 (1), 177 - 183 en
dc.identifier.issn 0264-410X en
dc.identifier.uri en
dc.description.abstract Background Though it is believed the switch from whole cell to acellular pertussis vaccine has contributed to the resurgence of pertussis disease, few studies have evaluated vaccine effectiveness (VE) and duration of protection provided by an acellular vaccine schedule including three primary doses but no toddler-age dose. We assessed this schedule in New Zealand (NZ), a setting with historically high rates of pertussis disease, and low but recently improved immunisation coverage. We further evaluated protection following the preschool-age booster dose. Methods We performed a nested case-control study using national-level healthcare data. Hospitalised and non-hospitalised pertussis was detected among children 6 weeks to 7 years of age between January 2006 and December 2013. The NZ National Immunisation Register provided vaccination status for cases and controls. Conditional logistic regression was used to calculate dose-specific VE with duration of immunity examined by stratifying VE into ages aligned with the immunisation schedule. Results VE against pertussis hospitalisation was 93% (95% confidence interval [CI]: 87, 96) following three doses among infants aged 5–11 months who received three compared to zero doses. This protection was sustained through children’s fourth birthdays (VE ⩾ 91%). VE against non-hospitalised pertussis was also sustained after three doses, from 86% (95% CI: 80, 90) among 5–11 month olds to 84% (95% CI: 80, 88) among 3-year-olds. Following the first booster dose at 4 years of age, the protective VE of 93% (95% CI: 90, 95) among 4-year-olds continued through 7 years of age (VE ⩾ 91%). Conclusions We found a high level of protection with no reduction in VE following both the primary course and the first booster dose. These findings support a 3-dose primary course of acellular vaccine with no booster dose until 4 years of age. en
dc.description.uri en
dc.language English en
dc.publisher Elsevier en
dc.relation.ispartofseries Vaccine en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from en
dc.rights.uri en
dc.rights.uri en
dc.title Age-specific effectiveness following each dose of acellular pertussis vaccine among infants and children in New Zealand en
dc.type Journal Article en
dc.identifier.doi 10.1016/j.vaccine.2016.11.004 en
pubs.issue 1 en
pubs.begin-page 177 en
pubs.volume 35 en
dc.description.version VoR - Version of Record en
dc.identifier.pmid 27866766 en en
pubs.end-page 183 en
pubs.publication-status Published en
dc.rights.accessrights en
pubs.subtype Article en
pubs.elements-id 547140 en Medical and Health Sciences en Population Health en Gen.Practice& Primary Hlthcare en
dc.identifier.eissn 1873-2518 en
pubs.record-created-at-source-date 2017-03-15 en 2016-11-18 en
pubs.dimensions-id 27866766 en

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace